Lyell ImmunopharmaLYEL
13F holders, Q3 2025 (September 30)2holders −4
0new positions
4sold out
$16.24avg. 13F price*
At the end of Q3 2025, 2 institutions reported holding Lyell Immunopharma Inc. (LYEL) in their 13F filings, down 4 from Q2 2025. 0 opened new positions and 4 sold out. The largest holders were Decheng Capital LLC ($9.7M) and Takeda Pharmaceutical Co. Ltd. ($891K).
- Company
- Lyell Immunopharma Inc.
- CUSIP
- 55083R104
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 4 | $16.0M |
All 13F filers, Q2 2025 → Q3 2025: 13,722 shares bought and 1,804,042 shares sold, net −1,790,320 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| Decheng Capital LLC | 1.69% | No change | 595,466 | $9.7M |
| Takeda Pharmaceutical Co. Ltd. | 5.45% | Add +33.3% | 54,887 | $891K |
"% of holder's portfolio" is LYEL's weight in each manager's 13F, not the share of Lyell Immunopharma Inc. the manager owns.